These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27735020)

  • 1. Ospemifene: a safe treatment of vaginal atrophy.
    Del Pup L
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3934-3944. PubMed ID: 27735020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of ospemifene in the breast.
    Berga SL
    Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
    DeGregorio MW; Zerbe RL; Wurz GT
    Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN; Pearce EF; Yancey AM; Forinash AB
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J; Portman D; Mabey RG;
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
    J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
    Pup LD; Sánchez-Borrego R
    Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
    Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
    Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
    [No Abstract]   [Full Text] [Related]  

  • 18. Ospemifene, vulvovaginal atrophy, and breast cancer.
    Wurz GT; Soe LH; DeGregorio MW
    Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ospemifene for the treatment of dyspareunia in postmenopausal women.
    Paton DM
    Drugs Today (Barc); 2014 May; 50(5):357-64. PubMed ID: 24918836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
    Eder SE
    Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.